Drug intelligence / Profile preview

JNJ-1761981

Development stage: Phase 1
Lead developer: Johnson & Johnson
Modality: Small Molecules
Administration: Intratumoral

Overview

JNJ-1761981 is an extended-release (ER) chemotherapy formulation developed by Johnson & Johnson for intratumoral administration. It is designed to deliver a sustained release of its cytotoxic payload, docetaxel, directly into solid tumor lesions. This localized delivery method aims to achieve high therapeutic concentrations at the site of the tumor while reducing systemic exposure and associated toxicities. JNJ-1761981 is being investigated in Phase 1 clinical trials for the treatment of locally advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), and is being studied both as a monotherapy and in combination with the PD-1 inhibitor cetrelimab.

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on JNJ-1761981.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JNJ-1761981.

Explore the full profile